```html

Quinine‑Related Cardiac Toxicity

Overview

Quinine is an alkaloid derived from the bark of the cinchona tree and has been used for centuries to treat malaria and, more recently, for nocturnal leg cramps. Although generally safe at therapeutic doses, quinine can cause direct toxicity to the heart, a condition known as quinine‑related cardiac toxicity. This toxicity can manifest as arrhythmias, conduction disturbances, or even heart failure.

**Who it affects** – Cardiac toxicity is most often reported in adults taking quinine for non‑malaria indications (e.g., leg cramps) or in people who inadvertently exceed prescribed doses. Patients with pre‑existing heart disease, electrolyte abnormalities, or certain drug interactions are particularly vulnerable.

Prevalence – Serious cardiac events are rare, estimated at <0.5–1 case per 10,000 quinine prescriptions in the United States<sup>[1]</sup>. However, because quinine is still available over‑the‑counter in some countries, under‑reporting is likely.

Symptoms

Symptoms can appear within hours of a dose increase or overdose, but delayed presentations (up to several days) have been documented.

Arrhythmias

• Ventricular tachycardia (VT) or fibrillation (VF) – rapid, life‑threatening rhythms that cause dizziness, palpitations, or loss of consciousness.
• Supraventricular tachycardia (SVT) – fast heart rate originating above the ventricles, often felt as a racing pulse.
• Premature ventricular contractions (PVCs) – “extra beats” that may cause a skipped‑heart sensation.

Conduction disturbances

• QRS widening – slower ventricular depolarization, seen on ECG.
• Prolonged PR interval or atrioventricular (AV) block – may cause fainting or fatigue.
• QTc prolongation – increases risk of torsades de pointes, a dangerous polymorphic VT.

Structural and functional changes

• Reduced ejection fraction – leading to symptoms of heart failure such as shortness of breath, swelling (edema), and exercise intolerance.
• Chest pain – can mimic ischemic angina because quinine affects coronary vasomotion.

Systemic signs that may accompany cardiac toxicity

• Dizziness or light‑headedness
• Syncope (fainting)
• Severe nausea, vomiting, or abdominal cramping (often a sign of quinine overdose)
• Hearing loss or tinnitus (ototoxicity) – another recognized quinine side effect that can coexist.

Causes and Risk Factors

Primary cause

Quinine interferes with cardiac ion channels, especially the fast sodium (Na⁺) and delayed rectifier potassium (K⁺) channels. This blockade can delay depolarization and repolarization, predisposing the myocardium to abnormal rhythms.

Risk factors

• High cumulative dose – doses >600 mg per day (the usual OTC dose for leg cramps) markedly increase risk.
• Renal or hepatic impairment – reduced clearance leads to higher plasma concentrations.
• Pre‑existing cardiac disease – e.g., ischemic heart disease, cardiomyopathy, congenital long QT syndrome.
• Electrolyte disturbances – especially hypokalemia, hypomagnesemia, or hyperkalemia.
• Concurrent QT‑prolonging drugs – macrolide antibiotics, fluoroquinolones, antipsychotics, or certain antiarrhythmics.
• Older age (≥65 years) – age‑related declines in drug metabolism and higher prevalence of comorbidities.
• Pregnancy – although quinine is sometimes used for nocturnal leg cramps in pregnancy, the altered pharmacokinetics increase exposure.

Diagnosis

Diagnosis hinges on a high index of suspicion, a clear medication history, and objective testing.

History and physical examination

• Document the indication, dose, formulation (tablet, syrup), and duration of quinine use.
• Ask about recent dose changes, over‑the‑counter preparations, or herbal supplements that might contain quinine.
• Perform a focused cardiovascular exam – checking pulse, blood pressure, jugular venous pressure, and signs of heart failure.

Electrocardiogram (ECG)

Essential for every suspected case. Look for:

• QTc >450 ms in men or >460 ms in women.
• QRS widening >120 ms.
• New AV block or bundle branch block.
• Presence of premature beats or tachyarrhythmias.

Laboratory studies

• Serum quinine level – not routinely available but useful in a research setting.
• Electrolytes (K⁺, Mg²⁺, Ca²⁺) – correct abnormalities promptly.
• Renal (creatinine, eGFR) and hepatic function tests – to assess clearance.
• Cardiac biomarkers (troponin, BNP) – to rule out ischemia or heart failure.

Imaging

• Echocardiography – evaluates ventricular function and wall motion abnormalities.
• Cardiac MRI – reserved for persistent unexplained dysfunction.

Exclusion of other causes

Because many drugs and electrolyte issues mimic quinine toxicity, clinicians must rule out alternative etiologies (e.g., coronary artery disease, thyroid disease, other anti‑arrhythmic agents).

Treatment Options

Treatment has two goals: (1) remove the offending agent and (2) stabilize cardiac electrophysiology.

Immediate measures

• Discontinue quinine immediately. If the patient is taking an over‑the‑counter formulation, advise stopping all doses.
• Provide cardiac monitoring in an emergency department or telemetry unit.
• Correct electrolyte abnormalities (e.g., intravenous potassium or magnesium).

Pharmacologic therapy

• IV Magnesium sulfate (2 g over 10 min) – first‑line for torsades de pointes or prolonged QTc.
• Beta‑blockers (e.g., metoprolol) – useful for supraventricular tachyarrhythmias and to blunt sympathetic surge.
• Lidocaine or Procainamide – may be considered for ventricular arrhythmias resistant to magnesium.
• Isoproterenol infusion – in select cases of bradyarrhythmia with high‑grade AV block.
• **Avoid** drugs that further prolong QT (e.g., macrolides, fluoroquinolones) while the patient is at risk.

Advanced interventions

• Cardioversion – synchronized cardioversion for hemodynamically unstable tachyarrhythmias.
• Implantable cardioverter‑defibrillator (ICD) – considered in patients with persistent ventricular arrhythmias after quinine cessation and who meet standard ICD criteria.
• Temporary pacing – for high‑grade AV block or symptomatic bradycardia.

Supportive care

• Oxygen supplementation if hypoxic.
• Intravenous fluids to maintain perfusion, unless contraindicated by heart failure.
• Analgesia for chest discomfort (avoid NSAIDs if renal function is impaired).

Follow‑up and long‑term management

• Repeat ECG 24–48 hours after quinine discontinuation to ensure QTc normalization.
• Outpatient cardiology review within 1‑2 weeks.
• Consider Holter monitoring for 24–48 hours if symptoms persist.

Living with Quinine‑Related Cardiac Toxicity

After the acute episode resolves, patients need a structured plan to prevent recurrence and to manage any lasting cardiac effects.

Medication review

• Never restart quinine without a physician’s explicit order.
• Provide a complete medication list to all health‑care providers, highlighting the prior toxicity.

Lifestyle adaptations

• Maintain a heart‑healthy diet rich in potassium (bananas, oranges) and magnesium (nuts, leafy greens).
• Stay hydrated; dehydration can concentrate quinine levels.
• Avoid excessive alcohol and stimulant substances (caffeine, cocaine) that can provoke arrhythmias.
• Engage in regular, moderate‑intensity exercise as tolerated; aim for 150 minutes per week.

Monitoring at home

• Check pulse at rest daily; report rates >100 bpm or irregular beats.
• Use a personal ECG device or smartphone‑linked monitor if available, especially after any new medication is added.
• Track symptoms (palpitations, dizziness, swelling) in a diary to share with your cardiologist.

Psychological support

Experiencing a cardiac event can cause anxiety. Consider counseling, support groups, or mindfulness programs to manage stress, which itself can trigger arrhythmias.

Prevention

• Use quinine only when clearly indicated – most leg‑cramp treatments are ineffective and carry higher risk.
• Adhere to the lowest effective dose (usually ≤200 mg per day) and never exceed the prescribed amount.
• Screen for cardiac disease and electrolyte imbalances before initiating quinine, especially in older adults.
• Educate patients about drug interactions; keep an up‑to‑date medication list.
• When prescribing quinine, consider obtaining a baseline ECG and repeat it within 1‑2 weeks.
• Encourage alternative therapies for nocturnal leg cramps (stretching, magnesium supplementation, adequate hydration) before resorting to quinine.

Complications

If not recognized promptly, quinine‑related cardiac toxicity can lead to:

• Sudden cardiac death from ventricular fibrillation.
• Persistent heart failure due to reduced ejection fraction.
• Development of a chronic conduction system disease requiring pacemaker implantation.
• Recurrent arrhythmias that may necessitate long‑term anti‑arrhythmic therapy.
• Secondary organ injury (renal failure) from hypotension during arrhythmic events.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Quinine side effects.” Updated 2023. https://www.mayoclinic.org
2. U.S. Food & Drug Administration. “Quinine-containing products: FDA safety communication.” 2022.
3. Cleveland Clinic. “Drug‑induced QT prolongation.” 2024. https://my.clevelandclinic.org
4. World Health Organization. “Guidelines for the treatment of malaria.” 2021.
5. National Institutes of Health, National Heart, Lung, and Blood Institute. “Arrhythmias and Drug‑induced Cardiotoxicity.” 2023.

```